A Meta-analysis of Trials on Aldose Reductase Inhibitors in Diabetic Peripheral Neuropathy

Nicolucci, Antonio; Carinci, Fabrizio; Cavaliere, D.; Scorpiglione, N.; Belfiglio, Maurizio; Labbrozzi, D.; Mari, E.; Benedetti, M. Massi; Tognoni, Gianni; Liberati, Alessandro

doi:10.1002/(sici)1096-9136(199612)13:12<1017::aid-dia252>3.0.co;2-z

Cited by 67 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many problems of the early ARI trials related to poor study design and the occlusion of patients with advanced neuropathy who would be unlikely to benefit from treatment. However, despite this, a meta-analysis was able to show some benefit of these agents in diabetic neuropathy [26].…”

Section: Aldose Reductase Inhibitorsmentioning

confidence: 94%

Treatments for diabetic neuropathy

Boulton

2001

Curr Diab Rep

View full text Add to dashboard Cite

The management of symptomatic diabetic sensory neuropathy presents a therapeutic challenge to the practicing physician. Two approaches are outlined in this article. First, symptomatic therapies, which will not influence the natural history of painful neuropathy, are discussed. These include, in addition to the stable glycemic control, tricyclic drugs, a number of anticonvulsant and antiarrhythmic agents, and opioid-like medications. Topical therapies and nonpharmalogic approaches are also discussed. With the exception of near normoglycemia, treatments that may slow the progression of neuropathy are experimental and include aldose reductase inhibitors, antioxidants, and other agents. Finally, the approach to patients without symptoms but with sensory loss is discussed.

show abstract

Section: Aldose Reductase Inhibitorsmentioning

confidence: 94%

Treatments for diabetic neuropathy

Boulton

2001

Curr Diab Rep

View full text Add to dashboard Cite

show abstract

“…However, despite the knowledge of pathophysiological details and despite clinical investigations for more than 20 years, the therapeutic efficacy of these compounds is still inclusive (Kador et al, 1990; Sorbinil Retinopathy Trial Research Group, 1990;Engerman and Kern, 1992;Nicolucci et al, 1996). Several compounds may have major drawbacks, such as the following:…”

Section: H Aldose Reductase Inhibitorsmentioning

confidence: 99%

Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

Verspohl

2012

Pharmacol Rev

View full text Add to dashboard Cite

“…However, to date, clinical studies have not shown convincing efficacy for this indication [60]. More recent studies, however, have reported antihyperglycaemic effects of single doses of M-16209 when administered to both SpragueDawley and streptozotocin rats [61], and enhanced insulin-stimulated glucose uptake (as measured by the euglycaemic clamp technique) following chronic treatment in anaesthetised Wistar rats [62] and Zucker fa/fa rats [63]; at higher doses there were also effects on insulin secretion [61]. Lowering of plasma levels of triglycerides, FFAs and total cholesterol levels was demonstrated after 13 days of treatment in Zucker fa/fa rats [63].…”

Section: Hydantoin Derivativesmentioning

confidence: 99%

Insulin-sensitising agents

Perry

Petrie

1998

Emerging Drugs

View full text Add to dashboard Cite

Current treatments for non-insulin-dependent diabetes mellitus (NIDDM; Type 2 diabetes) remain far from ideal. The presence of both hyperinsulinaemia and resistance to insulin action challenges the rationale of treatments that primarily boost insulin secretion. Novel therapeutic strategies focus mainly on increasing peripheral sensitivity to endogenous insulin, an approach that has the potential not only to treat but also to prevent Type 2 diabetes in high-risk individuals. Until recently, the most promising new class of agents appeared to be the thiazolidinedione derivatives. These agents are ligands for a specific subtype of peroxisome proliferator activated receptor (PPAR) and decrease plasma glucose levels while reducing circulating insulin and free fatty acid levels. At the time of writing (March 1998), the one approved thiazolidinedione had been withdrawn from the market in the UK after only nine weeks because of cases of hepatic dysfunction and failure occurring in patients in Japan and the USA. It is not yet clear whether this is a class effect and hence whether it will affect other similar agents in development. Reference is made to the current status of other agents in development.

show abstract

A Meta-analysis of Trials on Aldose Reductase Inhibitors in Diabetic Peripheral Neuropathy

Cited by 67 publications

References 0 publications

Treatments for diabetic neuropathy

Treatments for diabetic neuropathy

Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes

Insulin-sensitising agents

Contact Info

Product

Resources

About